Clinical trial
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery…
NCT00466752 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00466752 |
|---|---|
| Title | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer |
| Official title | A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer |
| Lead sponsor | University of Washington, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer |
| Intervention type | Drug, Genetic, Other, Procedure |
| Interventions | sorafenib tosylate, microarray analysis, immunohistochemistry staining method, gene expression analysis, needle biopsy, therapeutic conventional surgery, laboratory biomarker analysis, western blotting, RNA analysis |
| Enrollment | 5 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Nov 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: